Table 2

 Outcomes after extended etanercept exposure*

RCT trial arm
EtanerceptPlacebo
RCT Baseline (n  = 128)Week 96 of etanercept† (n = 95)RCT Baseline (n  = 129)Week 72 of etanercept‡ (n = 105)
*Values are mean (SE) unless otherwise indicated; †consisting of 72 weeks of open label etanercept and 24 weeks of RCT etanercept; ‡consisting of 72 weeks of open label etanercept; §average of the scores for the last two questions of the BASDAI on duration and intensity of morning stiffness.
ASAS component
Patient’s global assessment (0–100)63.2 (1.5)26.6 (2.6)63.3 (1.6)28.4 (2.3)
Back pain (0–100)61.7 (1.8)24.3 (2.6)63.7 (1.8)27.5 (2.6)
BASFI (0–100)51.1 (1.8)25.4 (2.4)56.8 (1.8)32.3 (2.5)
Inflammation§ (0–100)60.9 (1.9)22.8 (2.6)65.3 (1.8)28.0 (2.4)
CRP 1.8 (0.2)0.5 (0.1)2.0 (0.2)0.7 (0.1)